Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from SRPT

Sarepta Crashes 37% After Its Gene Therapy Flops Its Biggest-Ever Test

Sarepta Therapeutics' gene therapy, Elevidys, faces an uphill regulatory journey, analysts said Tuesday on mixed test results.

Investors Business Daily

Sarepta Plummets Despite Winning FDA Nod For $3.2 Million Gene Therapy

Sarepta Plummets Despite Winning FDA Nod For $3.2 Million Gene Therapy

Sarepta won approval Thursday for its highly anticipated Duchenne muscular dystrophy gene therapy. SRPT stock yo-yoed in response.

Investors Business Daily

Sarepta Therapeutics Dives On An Unexpected Holdup For Its Gene Therapy

Sarepta Therapeutics Dives On An Unexpected Holdup For Its Gene Therapy

The FDA pushed back its review of a highly anticipated gene therapy from Sarepta Therapeutics on Wednesday, prompting SRPT stock to tumble.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Dow Jones Futures Rise In Dangerous Market; Sarepta Soars On FDA News

Sideways action is far more dangerous than a bear market because it lures investors in. Here's what to do now. Sarepta surged on an FDA panel vote.

Investors Business Daily

Sarepta Stock Catapults Higher After Eking Out A Narrow Win In Its Gene Therapy Battle

Shares of SRPT stock launched Monday after FDA advisors voted late Friday in support of a highly anticipated gene therapy from Sarepta.

Investors Business Daily

Sarepta Tumbles As Report Of Internal FDA Strife Scorches Its Gene Therapy

Several FDA staffers were leaning toward rejecting a highly watched gene therapy from Sareptas, according to a report Thursday.

Investors Business Daily

Sarepta Crashes On An Unexpected Roadblock For Its Gene Therapy

In a surprise decision, the FDA will hold an advisory committee to discuss Sarepta's gene therapy, and SRPT stock tanked Friday.

Investors Business Daily

inkl

Read news from The Economist, FT, and more,
with one subscription

Sarepta Rockets And Breaks Out As FDA Smooths The Path For Its Gene Therapy

Sarepta Rockets And Breaks Out As FDA Smooths The Path For Its Gene Therapy

Sarepta could snag an accelerated approval for its muscular dystrophy gene therapy, analysts suggested Wednesday as SRPT stock rocketed.

Investors Business Daily

Sarepta Surges As It Nears The Finish Line With A Muscular Dystrophy Gene Therapy

Sarepta Surges As It Nears The Finish Line With A Muscular Dystrophy Gene Therapy

The FDA said Monday it will perform a speedy review of Sarepta Therapeutics' muscular dystrophy gene therapy, and SRPT stock jumped.

Investors Business Daily

Dow Jones Futures Fall: Market Rally Reeling As Fed's Powell Signals Higher Peak Rate

Dow Jones Futures Fall: Market Rally Reeling As Fed's Powell Signals Higher Peak Rate

Futures fell after the stock market sold off Wednesday on Fed chief Jerome Powell hinting at slower rate hikes but also a higher peak rate.

Investors Business Daily

Why IBD Stock Of The Day Sarepta Just Snagged A Price Target Hike Over Pfizer

Why IBD Stock Of The Day Sarepta Just Snagged A Price Target Hike Over Pfizer

IBD Stock Of The Day Sarepta will lead the gene therapy market in treating a form of muscular dystrophy, an analyst said Monday.

Investors Business Daily

Sarepta Reports One Heart Inflammation Case In Duchenne Gene Therapy Trial

Sarepta Reports One Heart Inflammation Case In Duchenne Gene Therapy Trial

Sarepta Therapeutics Inc (NASDAQ:SRPT) shared new functional data across multiple studies from the SRP-9001 (delandistrogene moxeparvovec) program for Duchenne muscular dystrophy. SRP-9001 is an investigational gene therapy under development in partnership with Roche Holdings AG (OTC:RHHBY). Results from Cohort 1 demonstrated a 3.8-point improvement and 3.2-point improvement on the Duchenne functional scale 52 weeks after…

Where Sarepta Therapeutics Stands With Analysts

Where Sarepta Therapeutics Stands With Analysts

Over the past 3 months, 5 analysts have published their opinion on Sarepta Therapeutics (NASDAQ:SRPT) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Sarepta Bets On GenEdit's Nanoparticles' In $57M Gene Editing Partnership

Sarepta Bets On GenEdit's Nanoparticles' In $57M Gene Editing Partnership

Sarepta Therapeutics Inc (NASDAQ: SRPT) will pay GenEdit up to

Get all your
news in one place.

100’s of premium titles.
One news app.

Analyst Ratings For Sarepta Therapeutics

Over the past 3 months, 6 analysts have published their opinion on Sarepta Therapeutics (NASDAQ:SRPT) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

1

People

Linda Yaccarino

Joseph Schwartz

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

231,662 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play